Adrenocortical Hyperfunction: Clinical Trials

4 trials for Adrenocortical Hyperfunction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Recruiting 4

Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat, Placebo - Hypertension, Hypercortisolemia
Phase 4RecruitingRECORDATI GROUP632026-08-262026-10-28
Statin Combined with Amlodipine Treats Primary Aldosteronism
Simvastatin combined with Amlodipine besylate, Simvastatin combined with Spironolactone and Amlodipine besylate., Amlodipine besylate combined Spironolactone - Primary Aldosteronism, Statin
Phase 4RecruitingThird Military Medical University1802024-09-102024-11-22
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Eplerenone - Primary Aldosteronism, Hypertension
Phase 4RecruitingBrigham and Women's Hospital402022-12-152026-10-15
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Metarapone, Standardized antihypertensive therapy - Adrenal Incidentalomas, Cushing Syndrome
Phase 4RecruitingIRCCS Azienda Ospedaliero-Universitaria di Bologna502021-02-232025-01-30

Narrower conditions

Hypertension (3)  ·  Cushing Syndrome (2)  ·  Hyperaldosteronism (2)  ·  ACTH Syndrome, Ectopic (1)  ·  Adrenal incidentaloma (1)

Broader conditions

Adrenal Gland Diseases (4)  ·  Endocrine System Diseases (4)  ·  Cardiovascular Diseases (3)  ·  Vascular Diseases (3)  ·  Neoplasms (1)  ·  Paraneoplastic Endocrine Syndromes (1)  ·  Paraneoplastic Syndromes (1)

Interventions

Amlodipine (1)  ·  Eplerenone (1)  ·  Mineralocorticoid Receptor Antagonists (1)  ·  Osilodrostat (1)  ·  Spironolactone (1)

Sponsors

Brigham and Women's Hospital (1)  ·  IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)  ·  RECORDATI GROUP (1)  ·  Third Military Medical University (1)

Countries

United States (2)  ·  China (1)  ·  Italy (1)

Top investigators

Guido Di Dalmazi, MD (1)  ·  Irina Bancos, MD (1)

NIH funding

2025 (1)